Takeaway
When patients ask about unverified peptides, respond with curiosity about their underlying health goal. Then clearly explain the difference between FDA-approved medications and gray-market ones, and guide patients toward other evidence-based treatments.
Lifelong learning in clinical excellence | October 23, 2026 | 3 min read
By Christopher Robinson, MD, PhD, Johns Hopkins Medicine
The patient with the Wolverine Stack question
“Dr. Chris,” (I go by my first name to help patients see I’m just like them and they feel comfortable to ask anything), “I feel like the steroid injections are worsening my shoulder. Can I use the Wolverine Stack instead?” asked a 49-year-old man with worsening shoulder tendinopathy. He showed me a website from abroad selling injectable vials labeled “research use only.”
A friend of his reported healing like “Wolverine” after taking a peptide mixture of BPC-157 and TB-500, also known as the Wolverine Stack. He assumed that because peptides occur naturally in the body, they must be safe. I thought about how to reply.
Not all peptides are alike
Peptides are short chains of amino acids, typically between 2 to 40, with diverse biological effects. Insulin, tesamorelin, human growth hormone, and tirzepatide illustrate how some peptide-based medications have undergone rigorous clinical testing and received FDA approval for specific indications. In contrast, BPC-157, TB-500 (the Wolverine Stack), and other peptides promoted for tissue repair or anti-aging lack adequate human evidence to support the many advertised benefits. Promising animal studies aren’t substitutes for controlled clinical trials, although they are a start.
Understanding the regulatory landscape
FDA approval applies to specific drug products, not to “peptides” as a class. Legitimate drug compounding under federal sections 503A and 503B can address particular clinical needs, but compounded medications aren’t FDA-approved and permitted active pharmaceutical ingredients and preparation practices are subject to specific regulatory conditions.
In July 2026, an FDA advisory committee recommended that six peptides, including BPC-157 and TB-500, be considered for the 503A bulk-substances list, where a patient can get a peptide compounded with a prescription. These were nonbinding recommendations, not approvals, but the FDA tends to side with the recommendations. Another interim access policy submitted to the White House for federal review in October 2026 remains pending.
Additionally, online products labeled “research use only” aren’t suitable for patients simply because they’re readily purchasable. Product identity, concentration, sterility, and contaminants may be uncertain.
Back to the Wolverine Stack question
When responding to the patient’s question about the Wolverine Stack, I used the below framework as a guide.
What to discuss with patients
1. Start with curiosity: “What are you hoping this treatment will accomplish?”
2. Ask for the exact product, dose, route, source, and duration; review other medications and medical conditions.
3. Request a photograph of the vial or package or the product itself if the patient has it.
4. Explain what’s established, what remains unknown, and why self-injecting an unverified product carries risks, including infection, dosing errors, immune reactions, and unexpected systemic effects.
If a patient is already using a peptide, document the exposure, assess for adverse effects, and discourage continued use of unverified injectables. Report suspected serious reactions through the FDA’s MedWatch. Offer evidence-based alternatives or, when appropriate, enrollment in a properly supervised clinical trial assessing peptides.
Key takeaway points
1. “Peptide” describes a string of amino acids, not proven safety or efficacy.
2. FDA approval, lawful compounding, and gray-market sales are very different categories.
3. The best response to a patient’s question is respectful, specific, and centered on the their underlying concern.
4. Remember, we’re here to help patients and make them feel comfortable.
“Thanks, Dr. Chris,” the patient said after I’d explained most of the above. We were then able to enroll him in a clinical trial.
Patients rarely ask about peptides just to learn regulatory classifications. They ask because they want relief, recovery, or hope. Our responsibility is to preserve that trust while helping them make informed decisions.
This piece expresses the views solely of the author. It does not necessarily represent the views of any organization, including Johns Hopkins Medicine.